Nothing Special   »   [go: up one dir, main page]

EA201070912A1 - OXIMA DERIVATIVES AS HSP90 INHIBITORS - Google Patents

OXIMA DERIVATIVES AS HSP90 INHIBITORS

Info

Publication number
EA201070912A1
EA201070912A1 EA201070912A EA201070912A EA201070912A1 EA 201070912 A1 EA201070912 A1 EA 201070912A1 EA 201070912 A EA201070912 A EA 201070912A EA 201070912 A EA201070912 A EA 201070912A EA 201070912 A1 EA201070912 A1 EA 201070912A1
Authority
EA
Eurasian Patent Office
Prior art keywords
oxima
derivatives
compounds
hsp90 inhibitors
present
Prior art date
Application number
EA201070912A
Other languages
Russian (ru)
Other versions
EA019156B1 (en
Inventor
Юн К. Чэнь
Эрик Ван Ко
Прасуна Гунтупалли
Джон Дэвид Лосон
Вольфганг Райнхард Людвиг Нотц
Джеффри А. Стаффорд
Хуонг-Тху Тон-Ну
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of EA201070912A1 publication Critical patent/EA201070912A1/en
Publication of EA019156B1 publication Critical patent/EA019156B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)

Abstract

Настоящее изобретение относится к соединениям, ингибирующим HSP90, имеющим формулув которой переменные определены в настоящем описании. Настоящее изобретение также относится к фармацевтическим композициям, наборам и изделиям, включающим такие соединения; способам и промежуточным соединениям, полезным для получения таких соединений; а также способам использования таких соединений.The present invention relates to compounds that inhibit HSP90, having the formula in which the variables are defined in the present description. The present invention also relates to pharmaceutical compositions, kits and articles comprising such compounds; methods and intermediates useful for preparing such compounds; as well as methods for using such compounds.

EA201070912A 2008-02-01 2009-01-30 Oxim derivatives as hsp90 inhibitors EA019156B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2572508P 2008-02-01 2008-02-01
US10159508P 2008-09-30 2008-09-30
PCT/US2009/032728 WO2009097578A1 (en) 2008-02-01 2009-01-30 Oxim derivatives as hsp90 inhibitors

Publications (2)

Publication Number Publication Date
EA201070912A1 true EA201070912A1 (en) 2011-08-30
EA019156B1 EA019156B1 (en) 2014-01-30

Family

ID=40436400

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070912A EA019156B1 (en) 2008-02-01 2009-01-30 Oxim derivatives as hsp90 inhibitors

Country Status (26)

Country Link
US (4) US8071766B2 (en)
EP (1) EP2252595B1 (en)
JP (1) JP5524084B2 (en)
KR (1) KR20100116206A (en)
CN (1) CN101983191B (en)
AR (1) AR071452A1 (en)
AU (1) AU2009208947B2 (en)
BR (1) BRPI0906598A2 (en)
CA (1) CA2713658C (en)
CL (1) CL2009000228A1 (en)
CR (1) CR11659A (en)
DO (1) DOP2010000236A (en)
EA (1) EA019156B1 (en)
EC (1) ECSP10010434A (en)
ES (1) ES2475206T3 (en)
GE (1) GEP20125718B (en)
IL (1) IL207227A0 (en)
MA (1) MA32104B1 (en)
MX (1) MX2010008269A (en)
MY (1) MY150596A (en)
NZ (1) NZ587207A (en)
PE (1) PE20091371A1 (en)
SG (1) SG187502A1 (en)
TW (1) TW200946531A (en)
WO (1) WO2009097578A1 (en)
ZA (1) ZA201005435B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2572263T3 (en) 2005-10-25 2016-05-31 Shionogi & Co Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors
AR061185A1 (en) 2006-05-26 2008-08-13 Chugai Pharmaceutical Co Ltd HETEROCICLICAL COMPOUNDS AS INHIBITORS OF HSP90. PHARMACEUTICAL COMPOSITIONS.
CL2008000629A1 (en) 2007-03-01 2008-08-29 Chugai Pharmaceutical Co Ltd MACROCICLICAL COMPOUNDS DERIVED FROM 6-ARIL-4-MERCAPTO- [1.3.5] TRIAZINA / [1.3] PIRIMIDIN-2-AMINA; PHARMACEUTICAL COMPOSITION, USEFUL IN THE TREATMENT OF CANCER.
KR20100017255A (en) 2007-04-24 2010-02-16 시오노기 앤드 컴파니, 리미티드 Aminodihydrothiazine derivatives substituted with cyclic groups
US8653067B2 (en) 2007-04-24 2014-02-18 Shionogi & Co., Ltd. Pharmaceutical composition for treating Alzheimer's disease
GB2449293A (en) * 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
GEP20125718B (en) * 2008-02-01 2012-12-25 Takeda Pharmaceuticals Co Oxim derivatives as hsp90 inhibitors
ES2738123T3 (en) 2008-06-13 2020-01-20 Shionogi & Co Heterocyclic sulfur-containing derivative that has β-secretase inhibitory activity
CN102186841A (en) 2008-10-22 2011-09-14 盐野义制药株式会社 2-aminopyridin-4-one and 2-aminopyridine derivative both having bace1-inhibiting activity
BR112012013854A2 (en) 2009-12-11 2019-09-24 Shionogi & Co oxazine derivatives.
WO2012057247A1 (en) 2010-10-29 2012-05-03 塩野義製薬株式会社 Fused aminodihydropyrimidine derivative
CA2816285A1 (en) 2010-10-29 2012-05-03 Shionogi & Co., Ltd. Naphthyridine derivative
TW201247635A (en) 2011-04-26 2012-12-01 Shionogi & Co Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them
ITTO20111013A1 (en) 2011-11-03 2013-05-04 Dac Srl PHARMACEUTICAL COMPOUNDS
JP2016501827A (en) 2012-10-24 2016-01-21 塩野義製薬株式会社 Dihydrooxazine or oxazepine derivative having BACE1 inhibitory action
WO2014107655A1 (en) * 2013-01-07 2014-07-10 St. Jude Children's Research Hospital Use of small molecule unfolder protein response modulators to treat tumors with active sonic hedgehog (ssh) signaling due to smoothened (smo) mutation
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
US9802978B2 (en) 2013-08-12 2017-10-31 Emory University Progesterone phosphate analogs and uses related thereto
CN113521314A (en) 2014-09-17 2021-10-22 纪念斯隆-凯特琳癌症中心 HSP 90-Targeted inflammation and infection imaging and treatment
US9868738B2 (en) 2014-09-19 2018-01-16 Merck Sharp & Dohme Corp. Diazine-fused amidines as BACE inhibitors, compositions, and their use
CR20200045A (en) 2016-04-07 2020-03-11 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
KR20190138871A (en) * 2017-04-24 2019-12-16 사무스 테라퓨틱스, 인코포레이티드 HSP90 Inhibitor Oral Formulations and Related Methods
US12110286B2 (en) 2017-05-26 2024-10-08 Cancer Research Technology Limited Benzimidazolone derived inhibitors of BCL6
US20190134219A1 (en) * 2017-09-15 2019-05-09 Ampersand Biopharmaceuticals, Inc. Inhibition of spontaneous metastasis via protein inhibitors of cysteine proteases
CN112568223B (en) * 2020-04-13 2023-04-21 辽宁先达农业科学有限公司 Herbicidal composition, application thereof and herbicide
CN111671749A (en) * 2020-06-12 2020-09-18 重庆医科大学 Application of dicoumarol in preparation of HBx protein stability inhibitor
CN112661668B (en) * 2020-12-31 2023-07-28 辽宁先达农业科学有限公司 N-substituted amide compound and preparation method thereof
CN114259564B (en) * 2021-11-30 2023-03-14 清华大学 Novel use of HSP90 inhibitors for blocking STAT3 mitochondrial transport and for treating asthma
CN115073458A (en) * 2022-07-04 2022-09-20 山东致泰医药技术有限公司 Preparation method of avibactam sodium
CN115381816A (en) * 2022-08-04 2022-11-25 武汉市金银潭医院(武汉市传染病医院) Application of VER50589 in preparing medicine for resisting enterovirus 71
CN117907491B (en) * 2024-03-12 2024-06-04 中国人民解放军军事科学院军事医学研究院 Double-derivatization technology-based abasic site LC-MS/MS analysis method

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1197466B (en) 1962-03-22 1965-07-29 Thomae Gmbh Dr K Process for the preparation of new 5, 6, 7, 8-tetrahydropyrido- [4, 3-d] pyrimidines
CA762455A (en) 1962-03-22 1967-07-04 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Pyrido-pyrimidines
GB8912336D0 (en) 1989-05-30 1989-07-12 Smithkline Beckman Intercredit Compounds
US5679683A (en) * 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
JP2000038350A (en) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd Diabetes therapeutic drug
EP1080092B1 (en) 1998-05-26 2008-07-23 Warner-Lambert Company LLC Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
CA2403558A1 (en) * 2000-03-23 2001-09-27 Merck & Co., Inc. Thrombin inhibitors
WO2001070269A1 (en) 2000-03-24 2001-09-27 Akzo Nobel N.V. Keratinocyte growth inhibitors and hydroxamic acid derivatives
AU9254801A (en) 2000-07-28 2002-02-13 Sloan Kettering Inst Cancer Methods for treating cell proliferative disorders and viral infections
AU2001280105A1 (en) 2000-08-22 2002-03-04 Kyowa Hakko Kogyo Co. Ltd. Methof of regulating apoptosis and apoptosis-regulatory polypeptide
JP4406205B2 (en) * 2000-11-02 2010-01-27 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Small molecule composition for binding to HSP90
WO2002069900A2 (en) 2001-03-01 2002-09-12 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
KR20020089883A (en) 2001-05-25 2002-11-30 주식회사 지인텍 Massage device
YU102503A (en) * 2001-06-28 2006-08-17 Pliva D.D. Fused pyrimidine dhfr inhibitors as antibacterials
JP2005139066A (en) 2001-12-14 2005-06-02 Hsp Research Institute Inc 2,3-dihydroxy-1h-quinolin-4-one oxime derivative and heat shock protein expression induction inhibitor
WO2003068776A1 (en) 2002-02-15 2003-08-21 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
AU2003229305A1 (en) 2002-05-17 2003-12-02 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
AU2003282512A1 (en) 2002-10-22 2004-05-13 The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Methods of reducing the activity of and reducing the concentration of a mutant kit protein
EP1457499A1 (en) 2003-03-12 2004-09-15 Tufts University School Of Medicine Inhibitors of extracellular Hsp90
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
JPWO2005018674A1 (en) * 2003-08-22 2006-10-19 協和醗酵工業株式会社 Drugs for diseases associated with immunoglobulin gene translocation
CA2537325A1 (en) 2003-09-19 2005-03-31 Gilead Sciences, Inc. Aza-quinolinol phosphonate integrase inhibitor compounds
AU2005206562A1 (en) 2004-01-23 2005-08-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EP1724268A4 (en) 2004-02-20 2010-04-21 Kirin Pharma Kk Compound having tgf-beta inhibitory activity and pharmaceutical composition containing same
DE102004041163A1 (en) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie New compounds with antibacterial activity
EP1814392A4 (en) 2004-11-02 2008-06-11 Conforma Therapeutics Corp Methods and compositions for treating chronic lymphocytic leukemia
WO2006050333A2 (en) 2004-11-02 2006-05-11 The Regents Of The University Of California Methods and compositions for modulating apoptosis
WO2006052795A2 (en) 2004-11-05 2006-05-18 University Of Rochester Methods of inhibiting the activity of hsp90 and/or aryl hydrocarbon receptor
EP1838152A2 (en) 2005-01-21 2007-10-03 Neurogen Corporation Imidazolylmethyl and pyrazolylmethyl heteroaryl derivatives
EP1853223B1 (en) 2005-02-02 2017-08-16 OncoSynergy, Inc. Local treatment of neurofibromas
KR100926399B1 (en) 2005-04-06 2009-11-12 아이알엠 엘엘씨 Diarylamine-containing compounds and compositions, and their use as modulators of steroid hormone nuclear receptors
US20070027150A1 (en) * 2005-04-14 2007-02-01 Bellamacina Cornelia R 2-Amino-quinazolin-5-ones
ES2552804T3 (en) 2005-05-04 2015-12-02 Evotec Ag Condensed heterocyclic compounds, and their compositions and uses
WO2006124904A2 (en) 2005-05-16 2006-11-23 Geron Corporation Cancer treatment by combined inhibition of telomerase and hsp90 activities
MX2007016183A (en) 2005-06-14 2008-03-10 Schering Corp The preparation and use of compounds as protease inhibitors.
EP1937258A2 (en) 2005-09-23 2008-07-02 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
JO2783B1 (en) 2005-09-30 2014-03-15 نوفارتيس ايه جي 2-Amino-7,8-Dihidro-6H-Pyrido(4,3-D)Pyrimidin-5-ones
WO2007082131A1 (en) 2006-01-09 2007-07-19 Bristol-Myers Squibb Company Process for the preparation of hydroxy substituted heterocycles
US7851468B2 (en) 2006-05-15 2010-12-14 Cephalon, Inc. Substituted pyrazolo[3,4-d]pyrimidines
JP5167250B2 (en) 2006-05-16 2013-03-21 メルク・シャープ・エンド・ドーム・コーポレイション Aminotetrahydropyran as a dipeptidyl peptidase IV inhibitor for the treatment or prevention of diabetes
WO2007139951A2 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
WO2007143630A2 (en) 2006-06-02 2007-12-13 Nexgenix Pharmaceuticals Treatment of neurofibromatosis with hsp90 inhibitors
CA2656825C (en) 2006-06-22 2013-12-10 Prana Biotechnology Limited Method of treatment and agents useful for same
US20080160520A1 (en) * 2006-06-22 2008-07-03 Angelika Amon Methods and Composition for Diagnosing and Treating Cancer
WO2008021981A2 (en) 2006-08-09 2008-02-21 Nexgenix Pharmaceuticals, Llc. Local treatment of epidermal and dermal hyperproliferative lesions
WO2008045529A1 (en) 2006-10-12 2008-04-17 Serenex, Inc. Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases
JP5366817B2 (en) 2006-11-15 2013-12-11 ジェネンテック， インコーポレイテッド Arylsulfonamide compounds
US20100111943A1 (en) 2007-03-22 2010-05-06 Medical College Of Georgia Research Institute, Inc Compositions and methods for inhibiting cancer metastasis
GB2449293A (en) * 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
GEP20125718B (en) * 2008-02-01 2012-12-25 Takeda Pharmaceuticals Co Oxim derivatives as hsp90 inhibitors

Also Published As

Publication number Publication date
US8618290B2 (en) 2013-12-31
MA32104B1 (en) 2011-02-01
CN101983191B (en) 2013-11-20
CA2713658A1 (en) 2009-08-06
US20120172321A1 (en) 2012-07-05
WO2009097578A1 (en) 2009-08-06
CL2009000228A1 (en) 2009-07-24
MX2010008269A (en) 2011-02-21
GEP20125718B (en) 2012-12-25
CR11659A (en) 2010-12-15
BRPI0906598A2 (en) 2015-07-07
US20110053873A1 (en) 2011-03-03
EP2252595B1 (en) 2014-03-26
MY150596A (en) 2014-01-30
AU2009208947A1 (en) 2009-08-06
EP2252595A1 (en) 2010-11-24
PE20091371A1 (en) 2009-10-03
ZA201005435B (en) 2011-11-30
IL207227A0 (en) 2010-12-30
ES2475206T3 (en) 2014-07-10
JP2011511003A (en) 2011-04-07
KR20100116206A (en) 2010-10-29
EA019156B1 (en) 2014-01-30
DOP2010000236A (en) 2010-09-30
TW200946531A (en) 2009-11-16
NZ587207A (en) 2012-05-25
ECSP10010434A (en) 2010-09-30
US20090305998A1 (en) 2009-12-10
AR071452A1 (en) 2010-06-23
SG187502A1 (en) 2013-02-28
CN101983191A (en) 2011-03-02
US8071766B2 (en) 2011-12-06
CA2713658C (en) 2016-07-05
AU2009208947B2 (en) 2014-02-06
JP5524084B2 (en) 2014-06-18
US20120264770A1 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
EA201070912A1 (en) OXIMA DERIVATIVES AS HSP90 INHIBITORS
EA201000642A1 (en) 2'-FLUOR-2'-DEOXYTETRAHYDROUridine AS CYTIDINDE DIAMINASE INHIBITORS
EA201170295A1 (en) INHIBITORS SMET
EA200970156A1 (en) PYRDISINOUS DERIVATIVES
EA201171151A1 (en) CRYSTALLINE TRIPEPTIDE EPOXYKETON-PROTEASE INHIBITORS
EA201200669A1 (en) PYRIDOPYRIMIDINONE INHIBITORS PI3Kα
EA201070256A1 (en) METHOD AND INTERMEDIATE CONNECTIONS FOR OBTAINING INHIBITORS INTEGRASES
EA201001680A1 (en) COMPOUNDS OF BENZOLSULPHONAMIDTIAOSOL AND OXAZOL
EA200800760A1 (en) PYRIDOPYRIMIDINONE INHIBITORS PI3Kα
EA201270339A1 (en) SUBSTITUTED DERIVATIVES OF XANTHINE
ATE522518T1 (en) INDAZOLE AND ISOINDOLE DERIVATIVES AS GLUCOKINASE ACTIVATE SUBSTANCES
EA201170772A1 (en) ORGANIC COMPOUNDS
EA201071320A1 (en) АКТИВАТОРЫ ГЛЮКОКИНАЗЫ
EA201100299A1 (en) ORGANIC COMPOUNDS
EA201170161A1 (en) 1,2,5-OXADIAZYLES AS INDLAMIN-2,3-DIOXYENASE INHIBITORS
EA201490596A1 (en) NEW DYHYDROCHINOLIN-2-IT DERIVATIVES
EA200702347A1 (en) METHOD FOR OBTAINING GLUCOPYRANOSYLESE-SUBSTITUTED DERIVATIVES OF BENZILBENZENE AND INTERMEDIATE PRODUCTS FOR THEIR OBTAINING
CO6321282A2 (en) PIPERIDINYLINDOL DERIVATIVES AS INHIBITORS OF ALDOSTERONA SINTASA
EA201001682A1 (en) Derivatives of phenyl and benzodioxynyl-substituted indazols
EA201490567A1 (en) NEW BICYCLIC DERIVATIVES OF DIHYDROCHINOLIN-2-IT
EA201490846A1 (en) NEW DERIVATIVES OF ARILHINOLINA
EA201270535A1 (en) PURINE DERIVATIVES APPLICABLE AS HSP90 INHIBITORS
EA201171211A1 (en) OXADIAZOL DERIVATIVES
EA201170282A1 (en) FUNGICIDAL N-CYCLO-ALKYL-N-BIPHENYLMETHYLKARBOXAMIDE DERIVATIVES
EA201190293A1 (en) TRIPOLIDA SPIRITS

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU